166 related articles for article (PubMed ID: 34576321)
1. Role of the Endocannabinoid/Endovanilloid System in the Modulation of Osteoclast Activity in Paget's Disease of Bone.
Paoletta M; Moretti A; Liguori S; Di Paola A; Tortora C; Argenziano M; Rossi F; Iolascon G
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576321
[TBL] [Abstract][Full Text] [Related]
2. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption.
Rossi F; Siniscalco D; Luongo L; De Petrocellis L; Bellini G; Petrosino S; Torella M; Santoro C; Nobili B; Perrotta S; Di Marzo V; Maione S
Bone; 2009 Mar; 44(3):476-84. PubMed ID: 19059369
[TBL] [Abstract][Full Text] [Related]
3. Aged G Protein-Coupled Receptor Kinase 3 (Grk3)-Deficient Mice Exhibit Enhanced Osteoclastogenesis and Develop Bone Lesions Analogous to Human Paget's Disease of Bone.
Rabjohns EM; Rampersad RR; Ghosh A; Hurst K; Eudy AM; Brozowski JM; Lee HH; Ren Y; Mirando A; Gladman J; Bowser JL; Berg K; Wani S; Ralston SH; Hilton MJ; Tarrant TK
Cells; 2023 Mar; 12(7):. PubMed ID: 37048054
[TBL] [Abstract][Full Text] [Related]
4. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL.
Neale SD; Smith R; Wass JA; Athanasou NA
Bone; 2000 Sep; 27(3):409-16. PubMed ID: 10962353
[TBL] [Abstract][Full Text] [Related]
5. Secreted phospholipase A2 type II is present in Paget's disease of bone and modulates osteoclastogenesis, apoptosis and bone resorption of human osteoclasts independently of its catalytic activity in vitro.
Allard-Chamard H; Haroun S; de Brum-Fernandes AJ
Prostaglandins Leukot Essent Fatty Acids; 2014; 90(2-3):39-45. PubMed ID: 24411720
[TBL] [Abstract][Full Text] [Related]
6. The Endocannabinoid/Endovanilloid System in Bone: From Osteoporosis to Osteosarcoma.
Rossi F; Tortora C; Punzo F; Bellini G; Argenziano M; Di Paola A; Torella M; Perrotta S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003519
[TBL] [Abstract][Full Text] [Related]
7. NFAM1 signaling enhances osteoclast formation and bone resorption activity in Paget's disease of bone.
Sambandam Y; Sundaram K; Saigusa T; Balasubramanian S; Reddy SV
Bone; 2017 Aug; 101():236-244. PubMed ID: 28506889
[TBL] [Abstract][Full Text] [Related]
8. PKCβII-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity.
Bellini G; Torella M; Manzo I; Tortora C; Luongo L; Punzo F; Colacurci N; Nobili B; Maione S; Rossi F
Pharmacol Res; 2017 Jan; 115():267-274. PubMed ID: 27919827
[TBL] [Abstract][Full Text] [Related]
9. Tartrate-resistant acid phosphatase 5b, but not periostin, is useful for assessing Paget's disease of bone.
Guañabens N; Filella X; Florez H; Ruiz-Gaspá S; Conesa A; Peris P; Monegal A; Torres F
Bone; 2019 Jul; 124():132-136. PubMed ID: 31051316
[TBL] [Abstract][Full Text] [Related]
10. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice.
Daroszewska A; van 't Hof RJ; Rojas JA; Layfield R; Landao-Basonga E; Rose L; Rose K; Ralston SH
Hum Mol Genet; 2011 Jul; 20(14):2734-44. PubMed ID: 21515589
[TBL] [Abstract][Full Text] [Related]
11. Osteoclast signaling-targeting miR-146a-3p and miR-155-5p are downregulated in Paget's disease of bone.
Stephens E; Roy M; Bisson M; Nguyen HD; Scott MS; Boire G; Bouchard L; Roux S
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165852. PubMed ID: 32485219
[TBL] [Abstract][Full Text] [Related]
12. Osteoclast function in Paget's disease and multiple myeloma.
Roodman GD
Bone; 1995 Aug; 17(2 Suppl):57S-61S. PubMed ID: 8579899
[TBL] [Abstract][Full Text] [Related]
13. The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy.
Rossi F; Bellini G; Luongo L; Torella M; Mancusi S; De Petrocellis L; Petrosino S; Siniscalco D; Orlando P; Scafuro M; Colacurci N; Perrotta S; Nobili B; Di Marzo V; Maione S;
Bone; 2011 May; 48(5):997-1007. PubMed ID: 21237298
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.
Roodman GD; Kurihara N; Ohsaki Y; Kukita A; Hosking D; Demulder A; Smith JF; Singer FR
J Clin Invest; 1992 Jan; 89(1):46-52. PubMed ID: 1729280
[TBL] [Abstract][Full Text] [Related]
15. The Paget's disease of bone risk gene PML is a negative regulator of osteoclast differentiation and bone resorption.
Wani S; Daroszewska A; Salter DM; van 't Hof RJ; Ralston SH; Albagha OME
Dis Model Mech; 2022 Apr; 15(4):. PubMed ID: 35229101
[TBL] [Abstract][Full Text] [Related]
16. A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis.
Lu B; Jiao Y; Wang Y; Dong J; Wei M; Cui B; Sun Y; Wang L; Zhang B; Chen Z; Zhao Y
Exp Mol Med; 2017 May; 49(5):e336. PubMed ID: 28524179
[TBL] [Abstract][Full Text] [Related]
17. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype.
Rea SL; Walsh JP; Ward L; Yip K; Ward BK; Kent GN; Steer JH; Xu J; Ratajczak T
J Bone Miner Res; 2006 Jul; 21(7):1136-45. PubMed ID: 16813535
[TBL] [Abstract][Full Text] [Related]
18. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.
Hiruma Y; Kurihara N; Subler MA; Zhou H; Boykin CS; Zhang H; Ishizuka S; Dempster DW; Roodman GD; Windle JJ
Hum Mol Genet; 2008 Dec; 17(23):3708-19. PubMed ID: 18765443
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic analysis of Paget's disease of bone identifies differentially methylated loci that predict disease status.
Diboun I; Wani S; Ralston SH; Albagha OM
Elife; 2021 Apr; 10():. PubMed ID: 33929316
[TBL] [Abstract][Full Text] [Related]
20. Optineurin regulates osteoblast function in an age-dependent fashion in a mouse model of Paget's disease of bone.
Hu X; Foster BL; Zhao B; Tseng HC; Wu YC; Ko CC
Bone; 2023 Dec; 177():116929. PubMed ID: 37802379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
